CAPRICOR, INC.
Exosome-based therapeutics for Duchenne muscular dystrophy and genetic diseases
- Sector
- Biotech
- Headquarters
- LOS ANGELES, CA
- Founded
- 2005
- Latest Form D
- $4.5M, Jan 2012
- Total capital
- $7.9M
- Federal grants
- $2.6M
- 2 awards · 2015–2016
- Rank in peer group#410 of 514
- Private capital raised
- $5.3M
- 2 Form D · last Jan 2012
- 177 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2018
- Rank in peer group#48 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients$1.7M
- Federal grantHealth and Human S · Phase II · Safety of Allogeneic Cardiosphere-Derived Cells for Dilated Cardiomyopathy$881K
- Private capital raisedForm D · SEC · 2nd filing$4.5M
- Private capital raisedForm D · SEC · 1st filing$800K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#48 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Rachel V. SmithResearcherExecutive OfficerLinked by $1.7M in grants as PI
- Earl M. Collier, Jr.DirectorNamed in SEC Form D filings
- Eduardo MarbanPromoterNamed in SEC Form D filings
- Linda S. MarbanExecutive Officer, DirectorNamed in SEC Form D filings
- Louis V. GrasmickDirectorNamed in SEC Form D filings
- Louis V. ManzoDirectorNamed in SEC Form D filings
Show all 7 people
- William V. AbrahamExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 40- PendingSARS-COV-2 Immunogenic Compositions And MethodsUSPTOApplication 19106167
- PendingCell Therapy Compositions And Methods Of ManufactureUSPTOApplication 19191968
- GrantedExosomal Nucleic Acid Vaccine Modularly Configured To Harness Multiple Antigen Presentation MechanismsUSPTOUS 12,433,941
Show all 40 patent records
- SARS-COV-2 Immunogenic Compositions And MethodsJul 2, 2026 · Application 19106167Pending
- Cell Therapy Compositions And Methods Of ManufactureNov 13, 2025 · Application 19191968Pending
- Exosomal Nucleic Acid Vaccine Modularly Configured To Harness Multiple Antigen Presentation MechanismsOct 7, 2025 · US 12,433,941Granted
- Arginase Bearing Vesicle Composition And Method Of UseApr 24, 2025 · Application 18920959Pending
- Targeted Vesicle Compositions And MethodsJan 30, 2025 · Application 18786287Pending
- Exosomal Nucleic Acid Vaccine Composition For Protection Against SARS-COV-2 Infection And DiseaseJan 2, 2025 · Application 18690177Pending
- Method For Surface Expression Of Membrane Proteins That Have A Cytoplasmic C-terminal TailOct 10, 2024 · Application 18577642Pending
- Methods And Compositions For Treating Skeletal Muscular DystrophyNov 30, 2023 · Application 18205313Pending
- Methods Of Treating Ocular Inflammation And Chemical Injuries Of The Eye With Extracellular VesiclesOct 31, 2023 · US 11,801,268Granted
- Methods Of Treating Systemic Graft- Versus-host Disease With Extracellular VesiclesOct 19, 2023 · Application 17983797Pending
- Methods And Compositions For Treating Skeletal Muscular DystrophySep 19, 2023 · US 11,759,482Granted
- Extracellular Vesicles Engineered to Be Loaded with Distinct RNA Cargo for Improved Therapeutic EfficacyJul 13, 2023 · Application 18011041Pending
- Selectable Marker Proteins, Expression Vectors, Engineered Cells And Extracellular Vesicles For The Production Of Virus-like Particles For Therapeutic And Prophylactic ApplicationsMay 18, 2023 · Application 17909971Pending
- Cardiosphere-derived Cell (cdc) Therapy For The Treatment Of Viral InfectionsMay 11, 2023 · Application 17906464Pending
- Methods Of Treating Systemic Graft-versus-host Disease With Extracellular VesiclesDec 20, 2022 · US 11,529,376Granted
- Therapeutically Active Cells And ExosomesJul 14, 2022 · Application 17608636Pending
- Method Of Preventing Or Treating Radiation-induced Dermatitis With Extracellular VesiclesJun 30, 2020 · US 10,695,293Granted
- Optimized Methods For Generation Of Cardiac Stem Cells From Cardiac Tissue And Their Use In Cardiac TherapyAug 6, 2019 · US 10,369,173Granted
- Optimized Methods For Generation Of Cardiac Stem Cells From Cardiac Tissue And Their Use In Cardiac TherapyFeb 6, 2018 · US 9,884,076Granted
- Processes For Producing Stable Exosome FormulationsDec 21, 2017 · Application 15531254Pending
- Processes For Producing Exosomes In Reduced Oxygen Culture ConditionsJun 9, 2016 · Application 14958784Pending
- Processes For Producing Stable Exosome FormulationsJun 9, 2016 · Application 14958804Pending
- SARS-COV-2 And Influenza Immunogenic Compositions And MethodsApplication 63412226Pending
- SARS-COV-2 Immunogenic Compositions And MethodsApplication 63411090Pending
- SARS-COV-2 Immunogenic Compositions And MethodsApplication 63373418Pending
- Method For Surface Expression Of Membrane Proteins That Have A Cytoplasmic C-terminal TailApplication PCTUS2022036553Pending
- Exosomal Nucleic Acid Vaccine Composition For Protection Against SARS-COV-2 Infection And DiseaseApplication 63243723Pending
- Method For Surface Expression Of Membrane Proteins That Have A Cytoplasmic C-terminal TailApplication 63220350Pending
- Extracellular Vesicles Engineered To Be Loaded With Distinct Rna Cargo For Improved Therapeutic EfficacyApplication PCTUS2021039716Pending
- Cardiosphere-derived Cell (cdc) Therapy For The Treatment Of Viral InfectionsApplication PCTUS2021023165Pending
- Selectable Marker Proteins, Expression Vectors, Engineered Cells And Extracellular Vesicles For The Production Of Virus-like Particles For Therapeutic And Prophylactic ApplicationsApplication PCTUS2021022200Pending
- Exosomal Nucleic Acid Vaccine Modularly Configured To Harness Multiple Antigen Presentation MechanismsApplication PCTUS2021022222Pending
- Exosomal Nucleic Acid Vaccine Modularly Configured To Harness Multiple Antigen Presentation MechanismsApplication 63110325Pending
- Exosomal Nucleic Acid Vaccine Modularly Configured To Harness Multiple Antigen Presentation MechanismsApplication 63061766Pending
- Extracellular Vesicles Engineered To Be Loaded With Distinct Rna Cargo For Improved Therapeutic EfficacyApplication 63045551Pending
- Therapeutically Active Cells And ExosomesApplication PCTUS2020031808Pending
- Exosomal Nucleic Acid Vaccine Modularly Configured To Harness Multiple Antigen Presentation MechanismsApplication 63000211Pending
- Cardiosphere-derived Cell (cdc) Therapy For The Treatment Of Viral InfectionsApplication 62992711Pending
- Exosomes Loaded With Nucleic Acid VaccineApplication 62990946Pending
- Exosomes Loaded With Nucleic Acid VaccineApplication 62989525Pending
Related companies, and why
- THIRD ELEMENT BIO INC.Similar federal contract value in Biotech · null in contracts
- FLUGEN, INC.Similar federal contract value in Biotech · null in contracts
- ZEBRA BIOLOGICS INCSimilar federal contract value in Biotech · null in contracts
- ONCOTRAP INCSimilar federal contract value in Biotech · null in contracts
- PolyCore Therapeutics LLC.Similar federal contract value in Biotech · null in contracts
- Kalyra Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .